NASDAQ: AIMD
Ainos Inc Stock

$0.74+0.01 (+1.37%)
Updated Feb 14, 2025
AIMD Price
$0.74
Fair Value Price
N/A
Market Cap
$10.23M
52 Week Low
$0.40
52 Week High
$3.10
P/E
-0.26x
P/B
0.57x
P/S
132.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$40.63k
Earnings
-$16.13M
Gross Margin
-352.8%
Operating Margin
-38,516.51%
Profit Margin
-39,705.8%
Debt to Equity
0.74
Operating Cash Flow
-$6M
Beta
74.25
Next Earnings
Mar 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A

AIMD Overview

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine AIMD's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Value
B
Growth
D
Momentum
C
Sentiment
F
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
D
AIMD
Ranked
#108 of 129

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$31.89A
$10.41A
$47.68A
View Top Medical Device Stocks

Be the first to know about important AIMD news, forecast changes, insider trades & much more!

AIMD News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AIMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AIMD is good value based on its book value relative to its share price (0.57x), compared to the US Medical Devices industry average (4.36x)
P/B vs Industry Valuation
AIMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AIMD due diligence checks available for Premium users.

Valuation

AIMD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.26x
Industry
42.37x
Market
37.92x

AIMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.57x
Industry
4.36x
AIMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AIMD's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.7M
Profit Margin
0%
AIMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AIMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$31.4M
Liabilities
$13.3M
Debt to equity
0.74
AIMD's short-term assets ($5.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIMD's long-term liabilities ($9.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
-$18.8k
Financing
-$1.5M
AIMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AIMD vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
AIMDD$10.23M+1.23%-0.26x0.57x
CUTR$9.71M+14.80%-0.07x-0.04x
SSKNC$11.47M-6.78%-1.03x1.23x
NUROC$8.94M-0.02%-0.96x0.56x
AEMDC$8.91M-2.38%-0.39x2.05x

Ainos Stock FAQ

What is Ainos's quote symbol?

(NASDAQ: AIMD) Ainos trades on the NASDAQ under the ticker symbol AIMD. Ainos stock quotes can also be displayed as NASDAQ: AIMD.

If you're new to stock investing, here's how to buy Ainos stock.

What is the 52 week high and low for Ainos (NASDAQ: AIMD)?

(NASDAQ: AIMD) Ainos's 52-week high was $3.10, and its 52-week low was $0.40. It is currently -76.16% from its 52-week high and 84.75% from its 52-week low.

How much is Ainos stock worth today?

(NASDAQ: AIMD) Ainos currently has 13,838,826 outstanding shares. With Ainos stock trading at $0.74 per share, the total value of Ainos stock (market capitalization) is $10.23M.

Ainos stock was originally listed at a price of $0.18 in Jan 19, 2021. If you had invested in Ainos stock at $0.18, your return over the last 4 years would have been 301.63%, for an annualized return of 41.57% (not including any dividends or dividend reinvestments).

How much is Ainos's stock price per share?

(NASDAQ: AIMD) Ainos stock price per share is $0.74 today (as of Feb 14, 2025).

What is Ainos's Market Cap?

(NASDAQ: AIMD) Ainos's market cap is $10.23M, as of Feb 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ainos's market cap is calculated by multiplying AIMD's current stock price of $0.74 by AIMD's total outstanding shares of 13,838,826.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.